



BioLayer Corporation Limited

10 September 2008

Company's Announcement Office
ASX Limited
Exchange Centre
20 Bridge Street
Sydney NSW 2000

ASX ANNOUNCEMENT / MEDIA RELEASE BIOLAYER SIGNS COMMERCIAL AGREEMENT WITH POWMRI AND BIO-LINK

Key Points:

- **Initial focus on developing a prognostic test for Parkinson's Disease, with a potential worldwide market size in excess of \$500m**
- **Filing of a new Australian provisional patent strengthens IP position**
- **Option for exclusive license for POWMRI intellectual property**
- **Collaboration supports BioLayer's strategic intent to partner with Australian companies to commercialise science opportunities**

Brisbane-based sciences company BioLayer Corporation Limited (ASX:BLS) announces that it signed a commercial agreement relating to the previously announced collaboration with Sydney-based Prince of Wales Medical Research Institute (POWMRI Limited) to develop an assay and other diagnostic tools relating to the early detection of neurodegenerative diseases, including Parkinson's Disease (Collaboration). The collaboration has been facilitated by Bio-Link, a commercialisation company with experience in biomedical and diagnostic areas.

The commercial agreement signed today grants BioLayer an option for an exclusive licence to develop existing POWMRI intellectual property under the Collaboration. BioLayer expects to exercise the option by February 2009, in conjunction with the achievement of the first development milestone.

BioLayer Corporation Limited ABN 75 070 028 625
Unit 4, 26 Brandl Street, Eight Mile Plains QLD 4113
Phone 07 3219 0085 Fax 07 3219 0553 Email contact@biolayercorp.com
Web www.biolayercorp.com

For personal use only



BioLayer Corporation Limited

BioLayer also announces the filing of a new Australian provisional patent that provides a completely different approach to protecting assay processes for the early detection of neurodegenerative diseases. Together with POWMRI's existing intellectual property, this patent will strengthen the Collaboration's intellectual property position to enable commercial exploitation to proceed. This patent application will have commercial use outside the Collaboration and expands the core intellectual property base that BioLayer has developed.

BioLayer CEO, Joe Maeji said "BioLayer is pleased to have finalised these arrangements and can now devote its efforts to achieving the various development milestones and in seeking early opportunities to generate revenues across research, diagnostic and therapeutic fields. In the first instance, these opportunities are likely to relate to data generation for research purposes".

The Institute's Executive Director, Professor Peter Schofield said, "POWMRI is delighted to formalise its relationship under this Collaboration with BioLayer". "It is pleasing to see the results of our research programs translating into commercial opportunities".

Parkinson's Disease is a debilitating disease with no known cure and few indicators prior to physical symptoms. The potential size of the market for a diagnostic in this field is still being investigated; however, early indications suggest this could be in excess of \$500 million globally. In the US, over 500,000 patients have been diagnosed with Parkinson's Disease with an annual estimated cost to treat of US\$11 billion**. Over the coming months, BioLayer will actively investigate opportunities to develop revenues streams and grant funding within this global market as the development plan is executed.

The transaction was facilitated by Bio-Link, a commercialisation company supported by the NSW Office for Science and Medical Research. Professor Peter Schofield said that Bio-Link played a key role in the negotiations and was an example of the assistance that the NSW Government is giving to support the commercialisation of medical research.

For further information please contact:

Dr Joe Maeji, CEO, BioLayer Corporation

Tel: 07 3219 0085; Email: joe.maeji@bio-layer.com

Professor Peter Schofield, Executive Director & CEO, Prince of Wales Medical Research Institute

Tel: 02 9399 1004; Email: p.schofield@powmri.edu.au

Paul Field, CEO, Bio-Link

Tel: 02 9209 4397; Email: p.field@bio-link.com

BioLayer Corporation Limited ABN 75 070 028 625
Unit 4, 26 Brandl Street, Eight Mile Plains QLD 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@biolayercorp.com
Web www.biolayercorp.com



BioLayer Corporation Limited

** Source: 12th International Congress of Parkinson's Disease and movement disorders 2008.

About BioLayer

BioLayer Corporation is an Australian sciences company providing end-to-end assay capabilities and components to support improved functionality in the solid phase of immunoassay development. BioLayer's proprietary coatings bind, orient and protect proteins such as antibodies in specific ways that enhance functionality. This results in dramatically improved immunoassay performance such as better sensitivity, and cost savings such as batch-to-batch reproducibility. BioLayer applies its coatings to develop novel biomarkers for a range of diseases such as Alzheimer's and Parkinson's Disease. BioLayer works with many types of solid phase materials and formats, like beads of different kinds, membranes and plates. For more information, visit www.bio-layer.com

About POWMRI

POWMRI Limited trades as Prince of Wales Medical Research Institute and is one of the largest centres of research on the brain and nervous system in Australia. Research is focused on both fundamental and clinical neuroscience addressing both neurological and psychiatric diseases. Officially opened on 8 November 1993, the Institute is situated on the Prince of Wales Hospital site, adjacent to the University of New South Wales. The Institute is an accredited National Health and Medical Research Council (NHMRC) independent research institute. For more information, visit www.powmri.edu.au.

About Bio-Link Partners Ltd.

Bio-Link Partners is a biotechnology business development company supported by the NSW Office for Science and Medical Research under a NSW BioFirst Grant. For more information, visit www.bio-link.com.

BioLayer Corporation Limited ABN 75 070 028 625
Unit 4, 26 Brandl Street, Eight Mile Plains QLD 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@biolayercorp.com
Web www.biolayercorp.com

For personal use only